Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.

Pediatric research - 1 Mar 2016

Nowicki Theodore S, Anderson Jennifer L, Federman Noah

Abstract excerpt

Progress has slowed substantially in improving survival rates for pediatric sarcomas, particularly in refractory and metastatic disease. Significant progress has been made in the field of tumor vaccines for such malignancies, which target established tumor antigens. While tumor vaccines have demonstrated safety and improved survival rates, they are inadequate in mediating the regression of established tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Cancer Vaccines
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Immunotherapy

Share to Programmed Cell Death 1 Receptor

Share to Receptors, Antigen, T-Cell

Share to Sarcoma

Source

Identifiers

PMID: 26595537
DOI: 10.1038/pr.2015.246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.PMID 26595537Read ↗

Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissuesSemantic proximity Read ↗

Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.Semantic proximity Read ↗

The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.Semantic proximity Read ↗

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.Semantic proximity Read ↗

Preclinical Pediatric Molecular Analysis for Therapy Choice (MATCH)Semantic proximity Read ↗

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialSemantic proximity Read ↗

Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Age-dependent tumor-immune interactions underlie immunotherapy response in pediatric cancerSemantic proximity Read ↗

Combination epigenetic-targeted therapy increases the immunogenicity of poorly immunogenic sarcomasSemantic proximity Read ↗

Recent Developments in Nanomedicine for Pediatric CancerSemantic proximity Read ↗

PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor.Semantic proximity Read ↗

Early-phenotype CAR-T cells for the treatment of pediatric cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.